1[1] Espersen GT, Mathiesen O, Grunnet N, Jensen S et al. Cytokine plasma levels and lymphocyte subsets in patient withnewly diagnosed insulin-dependent (type 1)diabetes mellitus before and following initial insulin treatment[J]. APMIS, 1997; 101(6):703-706.
2[2] Thomas MP, Hemming P, Jens M et al. Monokine antagonism is reduced in patients with IDDM[J]. Diabetes, 1994； 43（10）:1242-1247.
3[3] Molvig， Bak L，Christensen P et al. Endotoxin-stimulated human monocyte secretion of interleukin-1, tumur necrosis factor alpha, and prostaglandin E2 shows stable interindividual difference[J]. Scand J Immunol, 1988; 27（6）:705-716.
4[4] Harrsion LC, Honeyman MC, De Aizpurua HJ et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subject at risk of insulin-dependent diabetes[J]. Lancet, 1993; 341（5）:1365-1369.
5[5] Foulis AK, McGill M,Farquharson MA. Insulitis in type 1 (insulin-γ dependent)diabetes mellitus in man: Macrophages,lymphocytes,and interferon-γ containing cells[J]. J Pathol, 1991;165（2）:97-103.
6[6] Kroemer G, Wick G. The role of interleukin-2 in autoimmunity [J]. Immunol Today, 1989; 10（2）:245-251.
7[7] Kolb H, Zielasek J, Treichel U et al. Recombinant interleukin-2 enchanced spontaneous diabetes in BB rat[J]. Eur J Immunol, 1986; 16（2）:209-212.
8[8] Seino H, Takahashi K, Satoh J et al. Prevention of autoimmune diabetes with lymphotoxin in NOD mice[J]. Diabetes, 1993; 42（3）:398-404.
9[9] Jacob CO, Sadakazu A, Michie SA et al. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): Similarities between TNF-α and interleukin-1[J]. Proc Natl Acad Sci USA, 1992;87（6）: 968-973.
10[10] Ie J，Vilcek J. Tumor necrosis factor and interleukin-1:Cytokines with multiple overlapping biological activities[J]. Lab Invest, 1987; 56（3）:234-248.
